Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.